Spectral AINASDAQ: MDAI

Spectral AI Inc (NASDAQ:MDAI) announced that it has added two US clinical trial sites to its 2024 burn study, the University of California San Diego and the University of Utah. The medical diagnostics company said the addition of these new locations expands the total number of US clinical trial sites to 14.

DALLAS, July 03, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has added two new U.S. Clinical Trial Sites for its 2024 Burn Pivotal Study: the University of California San Diego and the University of Utah.

DALLAS, July 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has achieved 100% pediatric patient enrollment at burn centers for its 2024 pivotal study designed to validate the AI-driven algorithm used by its DeepView™ System for its burn indication.

Spectral AI Inc (NASDAQ:MDAI), the wound care diagnostics specialist, has been included in the Russell Microcap Index following the annual Russell Reconstitution, which took effect after the market close on June 28, 2024. The reconstituted Russell Microcap Index will commence trading on July 1, 2024.

DALLAS, July 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its inclusion in the Russell Microcap Index following the annual Russell Reconstitution, which took effect after the market close on June 28, 2024. The reconstituted Russell Microcap Index will commence trading on July 1, 2024.

Spectral AI Inc (NASDAQ:MDAI) announced it surpassed 90% of its enrollment target for pediatric patients at burn centers for its late-stage study evaluating its AI-driven DeepView System. The company's DeepView System utilizes proprietary multispectral imaging to distinguish between healthy and damaged tissue and can be used upon a child's arrival at the emergency department or burn center to provide immediate and accurate wound assessments in support of timely clinical decision-making for burn injuries.

Spectral AI Inc (NASDAQ:MDAI) told investors that it has provided support to Nasdaq and the state securities authorities in Florida, Louisiana and Texas to bring their attention to the potential market manipulation of the company's stock, primarily in the form of naked short selling. The company said the inquiry is being led by Erich Spangenberg, a member of its board of directors and its largest shareholder.

DALLAS, June 17, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will participate in the Northland Capital Markets Virtual Growth Conference on Tuesday, June 25, 2024.

Spectral AI Inc (NASDAQ:MDAI) announced that it has achieved 50% clinical trial site enrollment for its pivotal Deepview System study. The DeepView System's image processing algorithm uses multispectral imaging, which has been trained on a proprietary database of more than 340 billion data points, to aid healthcare providers in assessing the healing potential of a burn wound.